D-0992-2022 Class I Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

Recall Details

Product Type
Drugs
Report Date
June 8, 2022
Initiation Date
May 11, 2022
Termination Date
February 26, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4224 cartons

Product Description

Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

Reason for Recall

Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

Distribution Pattern

Distributed Nationwide in the USA

Code Information

Lot # GD01090, Exp 05/2022